SCHEMBL18936147

SCHEMBL18936147

O=[N+]([O-])c1cccc2c1O[CH]O2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.47
GPR35 Q9HC97 2/20 0.45
ALDH1A1 P00352 2/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
S100A4 P26447 2/20 0.40
HSD17B10 Q99714 1/20 0.39
MAOA P21397 1/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
PDE10A Q9Y233 1/20 0.37
PTPRC P08575 1/20 0.37
ERN1 O75460 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18936144 0.75 CHRNB4 (0.43) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL17288761 0.75 TDP1 (0.41) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
Ethane SCHEMBL28101016 0.74 TDP1 (0.52) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL15009561 0.73 AHR (0.47) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL30379968 0.72 TXNRD1 (0.62) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL6257481 0.72 TXNRD1 (0.62) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL2962443 0.72 MAPT (0.47) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL4486055 0.69 CHRNB4 (0.47) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL8975818 0.69 TDP1 (0.42) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL8975989 0.69 TDP1 (0.42) TDP1GPR35ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10251396-B2 Amide compound and use of same for noxious arthropod control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-04-09 US disclosed
US-20170295789-A1 AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-19 US disclosed
EP-3178322-A1 AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL Sumitomo Chemical Company Limited (JP) 2017-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170295789-A1 AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL OPRM1, TRPA1, L3MBTL3 TDP1 4542/4885GPR35 1296/4885ALDH1A1 1868/4885
US-10251396-B2 Amide compound and use of same for noxious arthropod control OPRM1, TRPA1, L3MBTL3 TDP1 4542/4885GPR35 1296/4885ALDH1A1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.